JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11

Benzinga · 1d ago
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.